How to File a Variation: Which Changes Require Prior Approval

1. Key takeaways

When information stated on a Philippine registration certificate changes, the holder has to apply to the FDA through the variation procedure and may implement the change only after approval. The changes that commonly require a variation are the product name, packaging, labelling, accessories, address changes and transfer of the holder. A variation attracts a fee and has to be processed within the applicable timeframe. Implementing a change without approval leaves the label inconsistent with the registered information, which triggers regulatory action.

• The test for whether a variation is needed is whether the change touches something stated on the certificate or on the approved label and instructions for use.
• Transfer of the holder is handled as a variation rather than as a new registration, provided the three preconditions are met.
• Label verification has become an enforcement point: a mismatch between the label in the market and the approved version moves the file into the FSCA process.
• Fees under the current schedule are in the hundreds of pesos per variation, while the AO 2024-0016 draft sets Minor at PHP 3,000 and Major at PHP 4,000.
• Because variations are frequent, the cumulative cost matters more than the cost of any single filing.

2. Legal basis

The variation route derives from Department of Health Administrative Order No. 2018-0002 of 26 January 2018, which ties the registered information to the certificate issued to the applicant. Fees currently follow the AO No. 50 s. 2001 basis, under which the variation fee compiled from third-party sources is PHP 510 per product per variation, including the 1 per cent LRF. The draft AO 2024-0016 would set device variations at PHP 3,000 for Minor and PHP 4,000 for Major, excluding the 1 per cent LRF. Label discrepancies are dealt with through a warning letter to the MAH, an FSCA report form within 14 calendar days, and corrective action completed within 60 calendar days. The post-market framework is AO No. 2025-0030, effective 6 May 2026.

3. Expert insights

The test for a variation is whether the approved content changes. There is only one question to ask: does the proposed change touch something stated on the registration certificate or on the approved label and instructions for use. A change of colour on the device, a change of pack size, an added warning in the instructions, a move of the manufacturing address, an added accessory: if any of these appears in the approved documents, it has to be notified. Conversely, a purely internal process adjustment that is not reflected in the approved documents usually does not require a variation, although the reasoning should be recorded rather than assumed.

Transfer of the holder is classified as a variation, not a new registration. This is one of the conveniences of the Philippine system. Changing the MAH is handled through the variation procedure, provided that the original agreement has been terminated, a new agreement has been signed, and the original certificate is in hand. The convenience is conditional: all three preconditions are required, and the variation still takes time and attracts a fee. Where the conditions cannot be met, the alternative is a fresh registration in the new holder’s name.

The cost of an unreported change rises sharply after 2026. AO No. 2025-0030 and the accompanying draft circulars strengthen the label verification mechanism. The FDA conducts physical checks of products to confirm that the label in the market matches the approved version; where a discrepancy is found, a warning letter is issued to the MAH, an FSCA report form has to be submitted within 14 calendar days, and corrective action has to be completed within 60 calendar days. A labelling omission is therefore no longer something to be corrected on the next print run; it becomes a formal regulatory event inside the FSCA process.

The gap between the old and new fee schedules is just as large on variations. Under the current old schedule the variation fee sits in the hundreds of pesos, around PHP 510 according to third-party compilation. Once AO 2024-0016 takes effect, a Minor variation is PHP 3,000 and a Major variation is PHP 4,000. The absolute amount is smaller than a registration fee, but variations are a high-frequency action, so the cumulative impact on a portfolio with many models and frequent label updates is not negligible.

4. Practical recommendations

• Create an approved-content snapshot. Immediately after the certificate is issued, archive the approved label, instructions for use, product name, manufacturing address and accessory list as the baseline, and compare every later change against that baseline.
• Put variations inside the management of change process. Any proposed change from R&D, marketing or supply chain should pass a regulatory gate that decides whether notification is required, before the change is scheduled for implementation.
• Get the label right at the application stage. Finalising the label before submission removes most of the later label variations, which are the most common and least valuable filings a company makes.
• Complete the three preconditions before transferring a holder. Terminate the old agreement, sign the new one and obtain the original certificate before starting the variation, not in parallel with it.
• Keep a change register that records decisions not to file. Where a change is judged not to require a variation, record the reasoning, so that the judgement can be defended if the FDA takes a different view during an inspection.

5. Verification checklist

• □ Whether the change touches approved content has been tested against the snapshot.
• □ Variation type determined: Minor or Major.
• □ Current fee confirmed against the eServices Order of Payment.
• □ Three preconditions for holder transfer met: termination, new agreement, original certificate.
• □ Physical label matches the approved version item by item.
• □ Implementation held until approval is granted.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including the Philippines. Our team prepares CMDN/CMDR dossiers to ASEAN CSDT structure, manages submissions and deficiency responses with the FDA Philippines, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com